Related references
Note: Only part of the references are listed.Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia
Thomas R. Chauncey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
I Am Older, Not Elderly, Said the Patient With Acute Myeloid Leukemia
Charles A. Schiffer
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7
Ingrid Furlan et al.
BLOOD (2009)
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
Ramiro Garzon et al.
BLOOD (2009)
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Jean-Luc Harousseau et al.
BLOOD (2009)
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
Keith Wheatley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-tine therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
Stefan Faderl et al.
BLOOD (2008)
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B
Muller Fabbri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
William Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7
Bjoern Rueter et al.
BLOOD (2007)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
Francis J. Giles et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian et al.
BLOOD (2007)
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Guillermo Garcia-Manero et al.
BLOOD (2006)
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia:: results from Cancer and Leukemia Group B 8461
Sherif S. Farag et al.
BLOOD (2006)
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
SD Gore et al.
CANCER RESEARCH (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia
SJ Liu et al.
CANCER RESEARCH (2005)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
JPJ Issa et al.
BLOOD (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
JG Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells
MI Klisovic et al.
LEUKEMIA (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
